HomeBiotechArcutis Announces Arcutis Cares(TM) Patient Assistance Program (PAP) For Financially Qualified Uninsured...

Arcutis Announces Arcutis Cares(TM) Patient Assistance Program (PAP) For Financially Qualified Uninsured and Underinsured Patients

Published on

Disclaimer

  • Arcutis Cares provides ZORYVE™ (roflumilast) cream 0.3% at no cost for financially eligible individuals who are uninsured or have Medicaid or Medicare Part D prescription coverage and cannot afford their medication
  • First ever PAP for a topical psoriasis product

WESTLAKE VILLAGE, Calif., Aug. 22, 2022 (GLOBE NEWSWIRE) —


Arcutis Biotherapeutics, Inc.


(Nasdaq: ARQT), an early commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced that Arcutis Cares, the first ever patient assistance program (PAP) for a topical psoriasis product, is open for enrollment. Financially eligible individuals who are uninsured or underinsured may apply for the program to receive ZORYVE (roflumilast) cream 0.3% at no cost.


“Our commitment to solving today’s biggest medical dermatology challenges doesn’t stop at developing new treatment options. It includes innovating to ensure as many people as possible who need our medications can receive them, for example by setting a responsible price and by offering patient access support programs for our products,” said Frank Watanabe, President and CEO of Arcutis. “We are proud that Arcutis Cares will provide ZORYVE at no cost to financially eligible individuals who are uninsured or underinsured, and believe it is a critical component to giving back to the community. Combined with the ZORYVE Direct Savings Card for individuals with commercial insurance, we aim to make ZORYVE affordable and accessible.”

Arcutis Cares is open for application to individuals who meet certain financial eligibility requirements, are uninsured or have Medicaid or Medicare Part D prescription coverage and cannot afford their medication.



Covered individuals must be 12 years or older, a resident of the United States, and prescribed ZORYVE for an FDA-approved use.



The application and the complete terms of the program are available by calling Arcutis Cares at 855-600-3755, or by visiting and downloading the form at

arcutiscares.com

and faxing to 855-237-9113. Terms and conditions are subject to change at any time.

Individuals with commercial drug insurance may be eligible for the ZORYVE Direct Savings Card. Individuals may pay as little as $25 if their commercial drug insurance covers ZORYVE, and $75 if their commercial drug insurance currently does not cover ZORYVE. More information on ZORYVE Direct can be found at

zoryve.com

.


INDICATION


ZORYVE (roflumilast) cream 0.3% is indicated for topical treatment of plaque psoriasis, including intertriginous areas, in patients 12 years of age and older.


IMPORTANT SAFETY INFORMATION


The use of ZORYVE is contraindicated in patients with moderate to severe liver impairment (Child-Pugh B or C).

The most common adverse reactions (≥1%) include diarrhea (3%), headache (2%), insomnia (1%), nausea (1%), application site pain (1%), upper respiratory tract infection (1%), and urinary tract infection (1%).

Please see full

Prescribing Information

.


About Arcutis

Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) is a medical dermatology company that champions meaningful innovation to address the urgent needs of patients living with immune-mediated dermatological diseases and conditions. With a commitment to solving the most persistent patient challenges in dermatology, Arcutis harnesses our unique dermatology development platform coupled with our dermatology expertise to build differentiated therapies against biologically validated targets. Arcutis’ dermatology development platform includes a robust pipeline with multiple clinical programs for a range of inflammatory dermatological conditions including scalp and body psoriasis, atopic dermatitis, and seborrheic dermatitis. For more information, visit

www.arcutis.com

or follow Arcutis on

LinkedIn

,

Facebook

, and

Twitter

.


Forward-Looking Statements

Arcutis cautions you that statements contained in this press release regarding matters that are not historical facts are forward-looking statements. These statements are based on the Company’s current beliefs and expectations. Such forward-looking statements include, but are not limited to, statements regarding the potential for ZORYVE to simplify disease management for care of plaque psoriasis; as well as the commercial launch of ZORYVE in plaque psoriasis, including product availability, pricing, and access. These statements are subject to substantial known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance, or achievements to be materially different from the information expressed or implied by these forward-looking statements. Risks and uncertainties that may cause our actual results to differ include risks inherent in our business, the impact of competition and other important factors discussed in the “Risk Factors” section of our Form 10-K filed with U.S. Securities and Exchange Commission (SEC) on February 22, 2022, as amended, as well as any subsequent filings with the SEC. You should not place undue reliance on any forward-looking statements in this press release. We undertake no obligation to revise or update information herein to reflect events or circumstances in the future, even if new information becomes available. All forward-looking statements are qualified in their entirety by this cautionary statement, which is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.


Contacts:




Media


Amanda Sheldon, Head of Corporate Communications


[email protected]




Investors


Eric McIntyre, Head of Investor Relations


[email protected]




Subject to financial eligibility requirements. Other terms and restrictions apply

.

Arcutis Cares

reserves the right to request additional information if needed and to change or discontinue the program at any time, without notice.

Arcutis Announces Arcutis Cares(TM) Patient Assistance Program (PAP) For Financially Qualified Uninsured and Underinsured Patients


Primary Logo

Latest News

REGENXBIO Presents Additional Positive Interim Data from the Phase I/II/III CAMPSIITE(TM) Trial of RGX-121 for the Treatment of MPS II (Hunter Syndrome) at the...

Disclaimer   PR Newswire - New data in Cohort 3 using pivotal program dose level demonstrates largest median...

Denali Therapeutics Announces New Interim Data from Phase 1/2 Study of DNL310 (ETV:IDS) in MPS II (Hunter Syndrome) at SSIEM 2022

Disclaimer Additional one-year data continue to show rapid and sustained normalization to healthy levels...

Real-World Administrative Claims Analysis Demonstrates That Almost Half of Migraine Patients Discontinue Barbiturate Use After Initiation of Nurtec ODT

Disclaimer   PR Newswire Results from this study demonstrate a robust and clinically meaningful reduction in...

FDA Grants Orphan Drug Designation for BioCryst’s ALK-2 Inhibitor, BCX9250, for the Treatment of Fibrodysplasia Ossificans Progressiva

Disclaimer RESEARCH TRIANGLE PARK, N.C., Aug. 31, 2022 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced...

More like this

FibroGen Announces Completion of Patient Enrollment in MATTERHORN, a Phase 3 Clinical Study of Roxadustat for the Treatment of Anemia in Patients with Lower...

Disclaimer - 141 MDS Patients Enrolled - - Topline Data Anticipated 1H:2023 - SAN FRANCISCO, Aug. 26,...

Travere Therapeutics to Present Abstracts at the Society for the Study of Inborn Errors of Metabolism Annual Symposium

Disclaimer SAN DIEGO, Aug. 25, 2022 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today...

BioCryst Presents Data Demonstrating >99 Percent Suppression of Alternative Pathway Complement Activity with BCX9930 in C3G Patients

Disclaimer Study represents first data with BCX9930 in C3G patients RESEARCH TRIANGLE PARK, N.C., Aug. 26,...

Iovance Biotherapeutics Initiates Biologics License Application (BLA) Submission for Lifileucel in Advanced Melanoma

Disclaimer First TIL Therapy BLA Submission Initiated with U.S. Food and Drug Administration Complete BLA Submission...

ChemoCentryx Announces TAVNEOS® (avacopan) Presentations at Upcoming Medical Conferences

Disclaimer SAN CARLOS, Calif., Aug. 24, 2022 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today...